ODYY on OTC

Odyssey Health, Inc.

Odyssey Health, Inc. is an American surgical and medical instruments and apparatus company.1 It is headquartered in Las Vegas, Nevada.1 Its shares trade on OTC under the symbol ODYY.1

Price unavailable

Last updated Oct 20, 2026.

Overview

-$1.7MNet income, fiscal 20252

Compare with enVVeno Medical Corp, ALR Technologies SG Ltd. or VIVOS INC, or pick any stock.

  • TickerODYY on OTC1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersLas Vegas, Nevada1
  • Incorporated inNV3
  • Business address2300 West Sahara Avenue, Suite 800-#4012, Las Vegas, Nv 891023
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Marketplace (“OTC”) and there is currently very little public market for our common stock.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Revenue56$0 in 2020
02018: $0$020182019: $0$020192020: $0$02020
Gross profit56$0 in 2020
02018: $0$020182019: $0$020192020: $0$02020
Operating income567-$3.8M in 2020+815% since 2018
-$30.0M-$20.0M-$10.0M02018: -$420.4K-$420.4K20182019: -$23.6M-$23.6M2019+5508%2020: -$3.8M-$3.8M2020−84%
Net income567-$4.3M in 2020+800% since 2018
-$30.0M-$20.0M-$10.0M02018: -$483.1K-$483.1K20182019: -$23.4M-$23.4M2019+4750%2020: -$4.3M-$4.3M2020−81%

Every line of the income statement as filed: the last 2 fiscal years, latest first.2

Period ending2025-07-312024-07-31
Research and development expense$0$55.2K
General and administrative expense$1.0M$2.1M
Loss from operations-$1.0M-$2.1M
Gain on sale of product candidates and related assets$0$16.4M
Impairment of investment in preferred stock of Oragenics, Inc.$0-$13.0M
Loss from change in fair value of Oragenics, Inc. common stock-$459.4K-$1.6M
Interest expense-$252.5K-$518.5K
Other (expense) income, net-$10.0K$9.3K
Net loss-$1.7M-$842.3K
Deemed dividend$0-$63.5K
Net loss attributable to common stockholders-$1.7M-$905.8K
Basic net loss per share attributable to common stockholders-$0.02-$0.01
Diluted net loss per share attributable to common stockholders-$0.02-$0.01
Shares used for basic net loss per share attributable to common stockholders104.7M shares97.1M shares
Shares used for diluted net loss per share attributable to common stockholders104.7M shares97.1M shares

Compare Odyssey Health, Inc. with another company

Corporate structure

Odyssey Health, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Odyssey Health, Inc.

  • Jonathan D. Lutz Filed SCHEDULE 13G/A on Odyssey Health, Inc., latest Nov 21, 2025 (3 filings since Jul 28, 2023)
  • Odyssey Health, Inc. Las Vegas, Nevada

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Odyssey Health, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Intangibles and goodwill

ItemLatestA year beforeChange
Finite-lived intangibles, net$011 Jul 31, 2024$49.9K11 Jul 31, 2023−100.0%

Properties, in its own words

As of July 31, 2025, we own no real property and lease minimal office space. Our principal address is located at 2300 West Sahara Avenue, Suite 800 - #4012, Las Vegas, Nevada, 89102.

Item 2 of the 10-K filed Oct 29, 2025.4

Leadership

Who has led Odyssey Health, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. J. Michael Redmond2019–2024

President

  1. J. Michael Redmond2019–2024

Chief financial officer

  1. Christine Farrell2021–2024

Chief operating officer

  1. Gregory W. Gironda2024
20202025
Board members and other officers (6)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorJoseph Michael Redmond named Jun 13, 202220
  • DirectorJohn Michael Gandolfo named Jun 13, 202220

Former names

  • Odyssey Group International, Inc.Dec 8, 2014 to Feb 18, 20223

Timeline

  1. Oct 5, 20268-K Entered a material agreement; New debt or obligation21
  2. May 26, 20268-K Entered a material agreement; New debt or obligation22
  3. May 11, 20268-K Entered a material agreement23
  4. Apr 24, 20268-K Entered a material agreement; Other events24
  5. Feb 3, 20268-K Entered a material agreement; New debt or obligation25
  6. Nov 19, 20258-K Entered a material agreement; New debt or obligation; Unregistered sale of shares26
  7. Oct 17, 20258-K Entered a material agreement; Other events27
  8. Oct 10, 20258-K Entered a material agreement; New debt or obligation28
  9. Oct 8, 20258-K Entered a material agreement; New debt or obligation29
  10. Sep 22, 20258-K Entered a material agreement; New debt or obligation30
  11. Aug 29, 20258-K Entered a material agreement; Unregistered sale of shares31
  12. Aug 15, 20258-K Entered a material agreement; New debt or obligation32
  13. Dec 11, 2019New chief executive J. Michael Redmond becomes CEO12

Filings

147 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 61 major events, 34 insider forms, 4 large holders, 1 private raises, 26 other. The latest 20:

  1. Oct 5, 20268-K CURRENT REPORT EDGAR
  2. Jun 12, 202610-Q FORM 10-Q FOR APR 2026 EDGAR
  3. May 26, 20268-K AMENDMENT #1 TO FORM 8-K EDGAR
  4. May 11, 20268-K EDGAR
  5. Apr 24, 20268-K CURRENT REPORT EDGAR
  6. Mar 12, 202610-Q FORM 10-Q FOR JAN 2026 EDGAR
  7. Feb 3, 20268-K CURRENT REPORT EDGAR
  8. Dec 30, 2025EFFECT EDGAR
  9. Dec 30, 2025424B3 EDGAR
  10. Dec 23, 2025CORRESP EDGAR
  11. Dec 19, 2025S-1 REGISTRATION STATEMENT EDGAR
  12. Dec 11, 202510-Q FORM 10-Q FOR OCT 2025 EDGAR
  13. Nov 21, 2025SCHEDULE 13G/A EDGAR
  14. Nov 19, 20258-K CURRENT REPORT EDGAR
  15. Oct 29, 202510-K FORM 10-K FOR JULY 2025 EDGAR
  16. Oct 17, 20258-K CURRENT REPORT EDGAR
  17. Oct 10, 20258-K EDGAR
  18. Oct 8, 20258-K CURRENT REPORT EDGAR
  19. Sep 22, 20258-K EDGAR
  20. Aug 29, 20258-K CURRENT REPORT EDGAR

The 147 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • Jonathan D. LutzSCHEDULE 13G/A, 3 filings Jul 28, 2023 to Nov 21, 202533

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Apr 14, 2022Raised $1.4 million in a private offering of equity Form D: $5 million offered in all Form D

SEC filer profile

How Odyssey Health, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAROdyssey Health, Inc.1
  • CIK0001626644
  • Employer ID (EIN)47-10221254
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company4
  • Incorporated inNevada4
  • Fiscal year endsJuly 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address2300 West Sahara Avenue, Suite 800-#4012, Las Vegas, NV 891021
  • Phone702-780-65591
  • Shares outstanding100,968,663 as of Jun 12, 20269
  • Public float$1.8M as of Jan 31, 20254
  • AuditorTurner, Stone & Company, L.L.P., Dallas, Texas PCAOB ID 76; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceDec 8, 20141
  • Filings274 in all: 8-K (98), 4 (40), 10-Q (33), 10-K (11), 3 (10), NT 10-Q (10), S-1/A (10), CORRESP (8)1
    All 30 form types

    UPLOAD (6), EFFECT (5), NT 10-K (5), S-1 (5), 424B3 (4), 10-Q/A (3), D (3), DEF 14A (3), PRE 14A (3), 10-K/A (2), 8-A12G (2), PRER14A (2), S-8 (2), 144 (1), 8-K/A (1), NTN 10K (1), RW (1), S-3 (1), SC 13D (1), SC 13G (1), SC 13G/A (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Oct 29, 2025
    Quarterly report (10-Q) Jun 12, 2026
    Proxy statement (DEF 14A) Oct 30, 2023
    Latest 8-K (8-K) Oct 5, 2026

Securities registered for trading

ClassSymbolExchange
ODYY

From the cover page of the 10-K filed Oct 29, 2025 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Odyssey Health, Inc. names in Item 1A of its 10-K filed Oct 29, 2025: 74 risks under these headings, as written.4

  • Risks Related to Our Financial Position and Need for Capital
  • We are a development stage company with little operating history, a history of losses and we cannot assure profitability.
  • There is substantial doubt about our ability to continue as a going concern.
  • Our actual financial position and results of operations may differ materially from management’s expectations.
  • Our limited operating history creates substantial uncertainty about future results.
  • Because we may never have net income from our operations, our business may fail.
  • Our ability to generate positive cash flows is uncertain.
  • We need to raise additional funds, and such funds may not be available on acceptable terms.
  • We may have difficulty raising additional capital, which could deprive us of the resources necessary to implement our business plan, which would adversely affect our business, results of operation and financial condition.
  • The capital requirements necessary to implement our business plan initiatives could pose additional risks to our business and stockholders.
  • Our independent registered public accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern in its report on our audited financial statements.
  • Raising additional capital by issuing securities or through debt financings or licensing arrangements may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates on terms unfavorable to us.
The other 63 risks
  • Risks Related to Our Technology, Development and Commercialization of our Product Candidates
  • Our success depends on the viability of our business model, which is unproven and may be unfeasible.
  • There are substantial inherent risks in attempting to commercialize newly developed products, and, as a result, we may not be able to successfully develop new products.
  • We will need to achieve commercial acceptance of our products, if cleared or approved, to generate revenues and achieve profitability.
  • We currently only have two product candidates, which are still in development, and we have not obtained authorization from any regulatory agency to commercially distribute the products in any country and we may never obtain such authorizations.
  • We face significant competition in an environment of rapid technological change, and our competitors may develop products that are more advanced or more effective than ours, which may adversely affect our financial condition and our ability to successfully market our products.
  • Risks Related to Our Reliance on Third Parties
  • We expect to rely on third parties for the worldwide marketing and distribution of our product candidates, who may not be successful in selling our products, if cleared or approved.
  • Our products, if cleared or approved, may be displaced by superior products developed by third parties.
  • We are, and will continue to be, significantly dependent, on outside scientists and third-party research institutions for our research and development in order to be able to commercialize our product candidates.
  • We will depend on third parties for the manufacture and distribution of our product candidates and products, if cleared or approved, and the loss of our third-party manufacturer and distributor could harm our business.
  • We may be unable to build an effective distribution network for our products, if cleared or approved.
  • Risks Related to Intellectual Property
  • We may be unable to adequately protect its proprietary and intellectual property rights.
  • We may not be able to protect intellectual property that we hope to acquire, which could adversely affect our business.
  • We may not be able to protect our trade names and domain names.
  • We may be forced to litigate to enforce or defend our intellectual property rights, to protect our trade secrets or to determine the validity and scope of other parties’ proprietary rights.
  • If our intellectual property protection is inadequate, competitors may gain access to our technology and undermine our competitive position.
  • We may be subject to various litigation claims and legal proceedings, including intellectual property litigation, such as patent infringement claims, which could adversely affect our business.
  • Risks Related to Government Regulation
  • Our products are subject to substantial federal and state regulations.
  • Obtaining FDA marketing authorization will be costly, may result in time-consuming delays and will subject us to ongoing compliance costs and regulatory risk for non-compliance.
  • We have and may continue to encounter substantial delays in planned clinical trials, or our planned clinical trials for other indications may fail to demonstrate the safety and efficacy of our product candidates to the satisfaction of applicable regulatory authorities.
  • We may be substantially dependent on third parties to conduct our clinical trials.
  • We may be required to suspend or discontinue clinical trials due to side effects or other safety risks that could preclude approval of our products.
  • If we are unable to obtain a reimbursement code from the U.S. Department of Health and Human Services so that our devices or drugs, following receipt of marketing authorization are covered under Medicare and Medicaid, this could have a negative impact on our intended sales and would have a material adverse effect on our business, financial condition and operating results.
  • If we fail to comply with healthcare laws, we could face substantial penalties and financial exposure, and our business, operations and financial condition could be adversely affected.
  • Our communications regarding product candidates, even while in development, are subject to extensive government scrutiny. We may be subject to governmental, regulatory and other legal proceedings related to advertising, promotion, and marketing, and communications with study subjects and healthcare professionals, which could have a significant negative effect on our business.
  • U.S. legislative or FDA regulatory reforms may make it more difficult and costly for us to obtain regulatory approval of our product candidates and to manufacture, market and distribute our products after marketing authorization is obtained.
  • Risks Related to our Business Operations
  • Failure to implement our business strategy could adversely affect our operations.
  • If our expenses are greater than anticipated, then we will have fewer funds with which to pursue our plan of operations and our financing requirements will be greater than anticipated.
  • Conducting any future clinical trials of our product candidates and any future commercial sales of a product candidate may expose us to expensive product liability claims, and we may not be able to maintain product liability insurance on reasonable terms or at all and may be required to limit commercialization of our product candidates.
  • We currently do not maintain product liability insurance as we do not have marketed products. At the time we require it, we may be unable to maintain sufficient product liability insurance.
  • If we are successful in acquiring and developing medical products and as we grow our business, our inability to manage such growth could harm our business.
  • We may indemnify our directors and officers against liability to us and our stockholders, and such indemnification could increase our operating costs.
  • We are a “smaller reporting company” under federal securities laws and we cannot be certain whether the reduced reporting requirements applicable to such companies will make our common stock less attractive to investors.
  • If we fail to develop or maintain an effective system of internal controls, we may not be able to accurately report our financial results or prevent financial fraud. As a result, current and potential stockholders could lose confidence in our financial reporting.
  • Our Articles of Incorporation provide that certain proceedings may only be instituted in the District Courts of Nevada, which may prevent or delay such proceedings and will increase the costs to enforce stockholder rights.
  • Our certificate of incorporation allows our board to create new series of preferred stock without approval by our stockholders, which could adversely affect the rights of the holders of our common stock.
  • Our inability to retain and properly insure against the loss of the services of our chief executive officer and other key personnel may harm our business and impede the implementation of our business strategy.
  • We are heavily dependent upon the ability and expertise of our management team and the loss of such individuals could have a material adverse effect on our business, operating results or financial condition.
  • People who provide services for us on a part-time consulting basis may be subject to conflicts of interest.
  • Our inability to attract, train and retain additional qualified personnel may harm our business and impede the implementation of our business strategy.
  • We participate in transactions and make tax calculations for which the ultimate tax determination may be uncertain.
  • Our ability to use net operating losses to offset future taxable income may be subject to certain limitations.
  • Challenges to our tax positions in U.S. or non-U.S. jurisdictions, the interpretation and application of recent U.S. tax legislation or other changes in U.S. or non-U.S. taxation of our operations could harm our business, revenue and financial results.
  • Investors could lose confidence in our financial reports, and the value of our common stock may be adversely affected, if our internal controls over financial reporting are found not to be effective by management or by our independent registered public accounting firm.
  • Our business and operations would suffer in the event of computer system failures, cyber-attacks or a deficiency in our cyber-security.
  • We may incur costs of addressing a cybersecurity incident.
  • Risks Related to Our Common Stock and Its Market Value
  • Your ownership will be diluted by future issuances of capital stock.
  • We have limited capitalization and may require financing, which may not be available.
  • Investors may experience dilution in the value of the shares of common stock.
  • If our business is unsuccessful, our stockholders may lose their entire investment.
  • Our common stock may never be listed on a national exchange and is subject to being removed from the OTC Marketplace.
  • Our common stock is deemed to be a “penny stock,” which may make it more difficult for investors to sell their shares due to suitability requirements.
  • The sale of shares of our common stock could cause the price of our common stock to decline.
  • A low market price would severely limit the potential market for our common stock.
  • If applicable, FINRA sales practice requirements could limit a stockholder’s ability to buy and sell our stock.
  • An investor’s ability to trade our common stock may be limited by trading volume.
  • A limited number of stockholders collectively own a significant portion of our common shares and may act, or prevent corporate actions, to the detriment of other stockholders.
  • A reverse split of our common stock could decrease our total market capitalization and increase, and may continue to increase, the volatility of our stock price.
  • A reverse stock split could increase our authorized but unissued shares of common stock, which could negatively impact a potential investor.
  • A decline in the price of our common stock could affect our ability to raise any required working capital and adversely affect our operations.
  • Trading of our common stock could be sporadic, and the price of our common stock may be volatile; we caution you as to the highly illiquid nature of an investment in our shares.
  • We have not paid any dividends and do not foresee paying dividends in the future.
  • If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline.

Legal proceedings

As of the date of this filing, we are currently not a party to any legal proceedings.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33